Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer's disease: A clinical trial

Zhou,Tiantian; Wang,Jindong; Xin,Cuiyu; Kong,Lingli; Wang,Chunxia

doi:10.3892/etm.2018.7124

Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer's disease: A clinical trial

Authors:
- Tiantian Zhou
- Jindong Wang
- Cuiyu Xin
- Lingli Kong
- Chunxia Wang
View Affiliations

Affiliations: Department of Geriatric Psychiatry, Qingdao Mental Health Center, Qingdao, Shandong 266034, P.R. China
Published online on: December 21, 2018 https://doi.org/10.3892/etm.2018.7124
Pages: 1625-1630
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Among Alzheimer's disease (AD) patients, it is very common to develop behavioral and psychological symptoms of dementia (BPSD), which has a close relation to the excess morbidity and mortality, greater healthcare use, earlier institutionalization, and caregiver burden. With evaluation of AD patients, the present study mainly aims to investigate whether citalopram would be efficient for BPSD, and examines citalopram's effects on cognitive function, caregiver distress, safety and tolerability. Eighty patients diagnosed with moderate AD and clinically significant BPSD from April 2015 to January 2016 were enrolled in this study. Patients randomly received memantine plus either citalopram (n=40, study group) or placebo (n=40, control group) in a 12‑week period. The target dose of memantine was 20 mg/day. The dose of citalopram was 10 mg/day in the beginning with planned titration to 30 mg/day over 2 weeks on the basis of response and tolerability. Blood routine, urine routine, biochemical tests, electrocardiogram and electroencephalogram were carried out for each patient every month routinely to check the change induced by using medication. Treatment Emergent Symptom Scale (TESS) was used to measure untoward effects every 2 weeks. All of the agitation/aggression, irritability/lability, night‑time behavioral disturbances, caregiver distress and Neuropsychiatric Inventory (NPI) total scores after treatment were found to be dramatically lower than those before treatment in both groups. Apathy, dysphoria and anxiety received lower scores in participants who received memantine combined with citalopram, compared to those before treatment. QTc interval prolongation was observed in 2 patients who were treated with 30 mg/day citalopramin. In conclusion, memantine combined with citalopram can more effectively improve the cognitive function, and reduce behavioral and psychological symptoms in patients with moderate AD. Cardiac adverse effects of citalopram are not common when the dose is <30 mg/day, which does not limit its practical application. Thus, citalopram has shown potential efficacy in adjunctive therapy of AD patients with BPSD.

View Figures

View References

1	Kam TI, Gwon Y and Jung YK: Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer's disease. Cell Mol Life Sci. 71:4803–4813. 2014. View Article : Google Scholar : PubMed/NCBI
2	Yoon PS, Ooi CH and How CH: Approach to the forgetful patient. Singapore Med J. 59:121–125. 2018. View Article : Google Scholar : PubMed/NCBI
3	Zheng Z, Wang J, Yi L, Yu H, Kong L, Cui W, Chen H and Wang C: Correlation between behavioural and psychological symptoms of Alzheimer type dementia and plasma homocysteine concentration. BioMed Res Int. 2014:3834942014. View Article : Google Scholar : PubMed/NCBI
4	Haibo X, Shifu X, Pin NT, Chao C, Guorong M, Xuejue L, Shiming B, Wenli F, Jun L, Mingyuan Z, et al: Prevalence and severity of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Chinese: Findings from the Shanghai three districts study. Aging Ment Health. 17:748–752. 2013. View Article : Google Scholar : PubMed/NCBI
5	Song JA and Oh Y: The association between the burden on formal caregivers and behavioral and psychological symptoms of dementia (BPSD) in Korean elderly in nursing homes. Arch Psychiatr Nurs. 29:346–354. 2015. View Article : Google Scholar : PubMed/NCBI
6	Savaskan E, Bopp-Kistler I, Buerge M, Fischlin R, Georgescu D, Giardini U, Hatzinger M, Hemmeter U, Justiniano I, et al: Recommendations for diagnosis and therapy of behavioral and psychological symptoms in dementia (BPSD). Praxis (Bern 1994). 103:135–148. 2014.(In German). View Article : Google Scholar : PubMed/NCBI
7	Savaskan E: Behavioral and psychological symptoms of dementia (BPSD): How to proceed. Ther Umsch. 72:255–260. 2015.(In German). View Article : Google Scholar : PubMed/NCBI
8	Farlow MR, Graham SM and Alva G: Memantine for the treatment of Alzheimer's disease tolerability and safety data from clinical trial. Drug Saf. 31:1577–1585. 2008. View Article : Google Scholar
9	Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC and Katona CL: Efficacy of memantine on behavioral and psychological symptoms related to dementia: A systematic meta-analysis. Ann Pharmacother. 42:32–38. 2008. View Article : Google Scholar : PubMed/NCBI
10	Rocca P, Marino F, Montemagni C, Perrone D and Bogetto F: Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: Preliminary findings from a naturalistic, retrospective study. Psychiatry Clin Neurosci. 61:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
11	De Deyn PP, Eriksson H and Svensson H: Study of 115 investigators: Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: A randomised, double-blind, parallel-group study. Int J Geriatr Psychiatry. 27:296–304. 2012. View Article : Google Scholar : PubMed/NCBI
12	McNeal KM, Meyer RP, Lukacs K, Senseney A and Mintzer J: Using risperidone for Alzheimer's dementia-associated psychosis. Expert Opin Pharmacother. 9:2537–2543. 2008. View Article : Google Scholar : PubMed/NCBI
13	Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y and Brodaty H: The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: A meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 22:475–484. 2007. View Article : Google Scholar : PubMed/NCBI
14	Rabinowitz J, Katz I, De Deyn PP, Greenspan A and Brodaty H: Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone. Int Psychogeriatr. 19:227–240. 2007. View Article : Google Scholar : PubMed/NCBI
15	Forloni G and Balducci C: Alzheimer's disease, oligomers, and inflammation. J Alzheimers Dis. 62:1261–1276. 2018. View Article : Google Scholar : PubMed/NCBI
16	Morgan BP: Complement in the pathogenesis of Alzheimer's disease. Semin Immunopathol. 40:113–124. 2018. View Article : Google Scholar : PubMed/NCBI
17	Paleacu D, Barak Y, Mirecky I and Mazeh D: Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: A 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry. 23:393–400. 2008. View Article : Google Scholar : PubMed/NCBI
18	Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CP, Francis PT, Lasheras B and Ramirez MJ: Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia. 43:442–449. 2005. View Article : Google Scholar : PubMed/NCBI
19	Lai MK, Tsang SW, Francis PT, Esiri MM, Keene J, Hope T and Chen CP: Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res. 974:82–87. 2003. View Article : Google Scholar : PubMed/NCBI
20	Lam LC, Tang NL, Ma SL, Zhang W and Chiu HF: 5-HT2A T102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer's disease. Int J Geriatr Psychiatry. 19:523–526. 2004. View Article : Google Scholar : PubMed/NCBI
21	Farina N, Morrell L and Banerjee S: What is the therapeutic value of antidepressants in dementia? A narrative review. Int J Geriatr Psychiatry. 32:32–49. 2017. View Article : Google Scholar : PubMed/NCBI
22	Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, et al: CitAD Research Group: Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA. 311:682–691. 2014. View Article : Google Scholar : PubMed/NCBI
23	Porsteinsson AP, Keltz MA and Smith JS: Role of citalopram in the treatment of agitation in Alzheimer's disease. Neurodegener Dis Manag. 4:345–349. 2014. View Article : Google Scholar : PubMed/NCBI
24	Porsteinsson AP, Smith JS, Keltz MA and Antonsdottir IM: Can antidepressant medication relieve agitation in Alzheimer's disease? Expert Rev Neurother. 14:969–971. 2014. View Article : Google Scholar : PubMed/NCBI
25	Underwood BR and Fox C: Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects. Evid Based Med. 19:1812014. View Article : Google Scholar : PubMed/NCBI
26	Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA and Gornbein J: The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 44:2308–2314. 1994. View Article : Google Scholar : PubMed/NCBI
27	Otero MC and Levenson RW: Lower visual avoidance in dementia patients is associated with greater psychological distress in caregivers. Dement Geriatr Cogn Disord. 43:247–258. 2017. View Article : Google Scholar : PubMed/NCBI
28	Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, et al: CitAD Research Group: Citalopram for agitation in Alzheimer's disease: Design and methods. Alzheimers Dement. 8:121–130. 2012. View Article : Google Scholar : PubMed/NCBI
29	Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, et al: CitAD Research Group: Time to response to citalopram treatment for agitation in Alzheimer Disease. Am J Geriatr Psychiatry. 23:1127–1133. 2015. View Article : Google Scholar : PubMed/NCBI
30	Hellen F, Supprian T, Salamon T and Lange-Asschenfeldt C: Resumption of food and fluid intake in Alzheimer's disease with severe apathy following intravenous citalopram. Psychiatry Clin Neurosci. 66:822012. View Article : Google Scholar : PubMed/NCBI
31	Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, Hayreh D, D'Angelo G, Benzinger T, Yoon H, et al: Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci USA. 108:14968–14973. 2011. View Article : Google Scholar : PubMed/NCBI
32	Ren QG, Gong WG, Wang YJ, Zhou QD and Zhang ZJ: Citalopram attenuates tau hyperphosphorylation and spatial memory deficit induced by social isolation rearing in middle-aged rats. J Mol Neurosci. 56:145–153. 2015. View Article : Google Scholar : PubMed/NCBI
33	Erickson MA and Banks WA: Neuroimmune axes of the blood-brain barriers and blood-brain interfaces: Bases for physiological regulation, disease states, and pharmacological interventions. Pharmacol Rev. 70:278–314. 2018. View Article : Google Scholar : PubMed/NCBI
34	Pimenova AA, Thathiah A, De Strooper B and Tesseur I: Regulation of amyloid precursor protein processing by serotonin signaling. PLoS One. 9:e870142014. View Article : Google Scholar : PubMed/NCBI
35	Deltheil T, Guiard BP, Cerdan J, David DJ, Tanaka KF, Repérant C, Guilloux JP, Coudoré F, Hen R and Gardier AM: Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology. 55:1006–1014. 2008. View Article : Google Scholar : PubMed/NCBI
36	Klyubin I, Cullen WK, Hu NW and Rowan MJ: Alzheimer's disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory. Mol Brain. 5:252012. View Article : Google Scholar : PubMed/NCBI
37	Wolkowitz OM, Wolf J, Shelly W, Rosser R, Burke HM, Lerner GK, Reus VI, Nelson JC, Epel ES and Mellon SH: Serum BDNF levels before treatment predict SSRI response in depression. Prog Neuropsychopharmacol Biol Psychiatry. 35:1623–1630. 2011. View Article : Google Scholar : PubMed/NCBI
38	van der Meij A, Comijs HC, Dols A, Janzing JG and Oude Voshaar RC: BDNF in late-life depression: Effect of SSRI usage and interaction with childhood abuse. Psychoneuroendocrinology. 43:81–89. 2014. View Article : Google Scholar : PubMed/NCBI
39	Ren QG, Wang YJ, Gong WG, Zhou QD, Xu L and Zhang ZJ: Escitalopram ameliorates forskolin-induced tau hyperphosphorylation in HEK239/tau441 cells. J Mol Neurosci. 56:500–508. 2015. View Article : Google Scholar : PubMed/NCBI
40	Wang YJ, Ren QG, Gong WG, Wu D, Tang X, Li XL, Wu FF, Bai F, Xu L and Zhang ZJ: Escitalopram attenuates β-amyloid-induced tau hyperphosphorylation in primary hippocampal neurons through the 5-HT1A receptor mediated Akt/GSK-3β pathway. Oncotarget. 7:13328–13339. 2016.PubMed/NCBI
41	Su F, Yi H, Xu L and Zhang Z: Fluoxetine and S-citalopram inhibit M1 activation and promote M2 activation of microglia in vitro. Neuroscience. 294:60–68. 2015. View Article : Google Scholar : PubMed/NCBI
42	Wenzel-Seifert K, Wittmann M and Haen E: QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int. 108:687–693. 2011.PubMed/NCBI
43	Vieweg WV, Hasnain M, Howland RH, Hettema JM, Kogut C, Wood MA and Pandurangi AK: Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med. 125:859–868. 2012.PubMed/NCBI